---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-247692"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:29:27.911610+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics completes SANRECO Phase 2 enrollment for divesiran in PV; topline data expected 3Q'26

## Summary
- 48 phlebotomy-dependent PV patients enrolled in global, randomized, double-blind, placebo-controlled study.
- Primary endpoint: proportion maintaining HCT <45% without phlebotomies between weeks 18 and 36.
- Phase 2 evaluates two dosing intervals (Q6W and Q12W); Phase 1 showed potential with Q6W dosing.
- Topline results anticipated in the third quarter of 2026.
- CEO cites divesiran as first-in-class siRNA targeting TMPRSS6 for significant unmet need in PV.

## SEC filing metadata
- accession: 0001193125-25-247692
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/0001193125-25-247692-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/sln-20251023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-247692
- JSON: https://secwatch.observer/filing/0001193125-25-247692.json
- Plain text: https://secwatch.observer/filing/0001193125-25-247692.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.